Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Peripheral T-cell Lymphomas

April 14, 2017

Join Steven Horwitz, MD and Laura Tang, PharmD, BCOP from Memorial Sloan Kettering Cancer Center as they present their expertise on a range of cases pertaining to peripheral T-cell lymphomas.

Peripheral T‑cell lymphomas (PTCL) are a heterogeneous group of aggressive non-Hodgkin’s lymphomas (NHL), accounting for about 10% of NHL. The most common subtypes include PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and anaplastic large cell lymphoma (ALCL). Enteropathy-associated T-cell lymphoma (EATL) is a rare subtype occurring in less than 5% of patients. Anthracycline-based multiagent chemotherapy is the standard first-line therapy.  However, with the exception of ALK-positive ALCL, other subtypes (PTCL-NOS, AITL and EATL) are associated with lower response rates to first-line chemotherapy alone and responses are not durable. Patients with these subtypes often receive high-dose therapy and autologous stem cell rescue (HDT/ASCR) following first-line therapy. Relapsed or refractory disease is managed with second-line chemotherapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient’s eligibility for transplant but treatment for this group of patients remains suboptimal.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Review the current therapeutic options for the treatment of newly diagnosed and relapsed/refractory peripheral T-cell lymphomas.
  • Develop an individualized treatment plan that integrates novel treatment options for the management of patients with relapsed/refractory peripheral T-cell lymphomas.
  • Counsel patients with peripheral T-cell lymphomas about available clinical trials.
Additional information
Supporters: 

This educational activity is supported by educational grants from Astellas; AstraZeneca; Bayer Healthcare Pharmaceuticals Inc.; Celgene Corporation; Eisai; Genomic Health, Inc.; Janssen Biotech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Sanofi-Genzyme; and Takeda Oncology. This activity is supported by educational funding provided by Amgen. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This educational activity is supported by an unrestricted education grant from Exelixis, Inc. This educational activity is supported by an independent educational grant from Merck.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
04/13/2017
Course expires: 
06/09/2017
Event starts: 
04/14/2017 - 3:15pm EDT
Event ends: 
04/14/2017 - 4:15pm EDT
Cost:
$0.00
Add to calendar: 

Steven Horwitz, MD
Memorial Sloan Kettering Cancer Center

Laura Tang, PharmD, BCOP
Memorial Sloan Kettering Cancer Center

 

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below discloses no relevant financial relationships:
Laura Tang, PharmD, BCOP

The faculty listed below discloses the following relevant financial relationships:
Steven M. Horwitz, MD
Amgen: Grant/Research Support
Celgene Corporation: Consulting Fees, Honoraria, Grant/Research Support
Huya Bioscience International: Consulting Fees, Honoraria
Infinity Pharmaceuticals, Inc.: Consulting Fees, Honoraria, Grant/Research Support
Kyowa Hakko Kirin Co., Ltd.: Scientific Advisor, Grant/Research Support
Millennium Pharmaceuticals, Inc.: Scientific Advisor, Grant/Research Support
Seattle Genetics, Inc.: Consulting Fees, Honoararia, Grant/Research Support
Genentech, Inc.: Grant/Research Support
Spectrum Pharmaceuticals: Grant/Research Support

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN (employed by NCCN until 2/7/17); Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser (employed by NCCN until 2/3/17)

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Hema Sundar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use.  Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity code: I00026235; Approval Number: 170001242

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-17-024-L01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing